Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT06071429

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
R3 Vascular Inc. (from the registry)
Registry
  • NCT NCT06071429
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06071429. Randomized; single masking; primary purpose treatment. Start 2025-04-11 (actual); primary completion 2028-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease
Acronym
ELITE-BTK
Condition
Chronic Limb-Threatening Ischemia
Intervention (Device)
MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold
Intervention (Device)
Percutaneous Transluminal Angioplasty (PTA)
Lead sponsor
R3 Vascular Inc. (class: industry)

Record details

Record id
cardio:ct-nct06071429
Content hash
7d434534aced34d39f8b12bac601da1b21a7216e85254d1570d56b1cf6797405